Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

About this update from Coloplast A/s Class B

The new 5-year strategy,  Impact4 , will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4 , we focus on four strategic priorities which are essential to our success and value creation: Ahead of the new strategic period, we are organising our businesses into two distinct business units: Chronic Care and Acute Care, as announced on 19 August 2025. This allows the company to respect the differences in market dynamics, customer needs, patient pathways and business models. As a consequence of the new business unit structure, a new Executive Leadership Team was also announced on 19 August 2025, to successfully lead the execution of the Impact4 strategy. “ Together with the rest of the Board of Directors and Executive Leadership Team at Coloplast, I am excited to present to you our new 5-year strategy, Impact4 . The strategic priorities we have laid out in Impact4 set a clear direction – one where our customers are at the centre of everything we do. We are reinvigorating our focus on delivering the best customer experience for our users, patients and clinicians across our offering of products, support and services, with the ambition to lead the market and win. I firmly believe our new strategy will create value for all our stakeholders – customers, shareholders, employees and partners.’’ says Lars Rasmussen, interim CEO of Coloplast. Key highlights of the day are: The Capital Markets Day will start at 10.30h CEST today with a plenary session, covering the introduction of the new Group strategy, Group financial update and the strategy for the Chronic Care business unit. In the afternoon, there will be a series of breakout sessions with Executive Leadership and other key representatives from Coloplast, covering a strategic update on US Chronic Care and Emerging Markets Chronic Care, Wound and Tissue Repair, Interventional Urology, Global Operations and People and Culture. The event will be held in person at the Clarion Hotel in Copenhagen, Denmark. To participate in the plenary session of the Capital Markets Day 2025 virtually, please follow the link here: Coloplast Capital Markets Day 2025 . All material from the Capital Markets Day will be made available during the day on Coloplast’s website: Investors . 1. The new financial ambition includes the following key assumptions: 2. In constant currencies; before special items 3. Introduction of reimbursement for transanal irrigation as of 1 October 2025 by Medicare Forward-looking statements The forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict. The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time. Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company’s financial results. Contacts: Investors: Aleksandra Dimovska Vice President, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted Munk Senior Director, Investor Relations  Tel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby Helvind Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Media: Peter Mønster Senior Media Relations Manager Tel. +45 4911 2623 Email: [email protected] Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.   Attachment

View stock analysis, news, and events for Coloplast A/s Class B